<DOC>
	<DOC>NCT00809783</DOC>
	<brief_summary>Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab</brief_summary>
	<brief_title>Extension Study Of Tanezumab In Osteoarthritis</brief_title>
	<detailed_description>This study was terminated on 27 October 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Must have participated in previous (specific) Phase 3 trials of Tanezumab in osteoarthritis Willing to comply with scheduled visits and treatment plan Is medically fit to participate in the trial in the judgement of the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Tanezumab OA arthritis</keyword>
</DOC>